Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients with Rheumatoid Arthritis.

Crins MHP, Terwee CB, Westhovens R, van Schaardenburg D, Smits N, Joly J, Verschueren P, Van der Elst K, Dekker J, Boers M, Roorda LD.

Arthritis Care Res (Hoboken). 2019 Sep 28. doi: 10.1002/acr.24077. [Epub ahead of print]

PMID:
31562795
2.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
3.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
4.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

5.

Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme.

Heslinga M, Van Den Oever I, Jonker DL, Griep EN, Griep-Wentink H, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters M, Van Schaardenburg D, Nurmohamed MT.

Scand J Rheumatol. 2019 Sep;48(5):345-352. doi: 10.1080/03009742.2019.1600718. Epub 2019 Jun 18.

PMID:
31210083
6.

Predicting Rheumatoid Arthritis in At-risk Individuals.

van Boheemen L, van Schaardenburg D.

Clin Ther. 2019 Jul;41(7):1286-1298. doi: 10.1016/j.clinthera.2019.04.017. Epub 2019 Jun 10.

PMID:
31196647
7.

Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis.

Blomjous BS, Boers M, Den Uyl D, Twisk J, Van Schaardenburg D, Voskuyl AE, Lems WF, Ter Wee MM.

Scand J Rheumatol. 2019 Jul;48(4):271-278. doi: 10.1080/03009742.2019.1570549. Epub 2019 May 28.

PMID:
31135239
8.

Symptoms associated with inflammatory arthritis are common in the primary care population: results from the joint symptoms survey.

Hider SL, Muller S, Helliwell T, Prior JA, Scott I, Lawton SA, Zwierska I, van Schaardenburg D, van der Helm-van Mil A, Raza K, Mallen CD.

Rheumatology (Oxford). 2019 Nov 1;58(11):2009-2014. doi: 10.1093/rheumatology/kez184.

PMID:
31079150
9.

Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis.

Turk SA, Rasch LA, van Schaardenburg D, Lems WF, Sanberg M, van Tuyl LHD, Ter Wee MM.

BMC Rheumatol. 2018 Jun 26;2:16. doi: 10.1186/s41927-018-0024-9. eCollection 2018.

10.

Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.

Turk SA, Heslinga M, Twisk J, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

Clin Exp Rheumatol. 2019 May-Jun;37(3):513. Epub 2019 Feb 15. No abstract available.

11.

The value of joint ultrasonography in predicting arthritis in seropositive patients with arthralgia: a prospective cohort study.

van Beers-Tas MH, Blanken AB, Nielen MMJ, Turkstra F, van der Laken CJ, Meursinge Reynders M, van Schaardenburg D.

Arthritis Res Ther. 2018 Dec 19;20(1):279. doi: 10.1186/s13075-018-1767-9.

12.

Depressive mood and low social support are not associated with arthritis development in patients with seropositive arthralgia, although they predict increased musculoskeletal symptoms.

Holla JFM, van Beers-Tas MH, van de Stadt LA, Landewé R, Twisk JWR, Dekker J, van Schaardenburg D.

RMD Open. 2018 Jun 27;4(1):e000653. doi: 10.1136/rmdopen-2018-000653. eCollection 2018.

13.

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project.

van Beers-Tas MH, Ter Wee MM, van Tuyl LH, Maat B, Hoogland W, Hensvold AH, Catrina AI, Mosor E, Stamm TA, Finckh A, Courvoisier DS, Filer A, Sahbudin I, Stack RJ, Raza K, van Schaardenburg D.

RMD Open. 2018 May 21;4(1):e000641. doi: 10.1136/rmdopen-2017-000641. eCollection 2018.

14.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

15.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

16.

Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.

Britsemmer K, van Schaardenburg D, Boers M, De Cock D, Verschueren P, Radner H, Smolen JS, van Tuyl LHD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):362-370. Epub 2018 Feb 26.

PMID:
29533752
17.

One-year Predictors of Presenteeism in Workers with Rheumatoid Arthritis: Disease-related Factors and Characteristics of General Health and Work.

Boot CRL, de Wind A, van Vilsteren M, van der Beek AJ, van Schaardenburg D, Anema JR.

J Rheumatol. 2018 Jun;45(6):766-770. doi: 10.3899/jrheum.170586. Epub 2018 Mar 1.

PMID:
29496893
18.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2018 Apr 1;57(4):771. doi: 10.1093/rheumatology/key056. No abstract available.

PMID:
29481646
19.

Clinically relevant discrepancies between different rheumatoid factor assays.

Falkenburg WJJ, von Richthofen HJ, Koers J, Weykamp C, Schreurs MWJ, Bakker-Jonges LE, Haagen IA, Lems WF, Hamann D, van Schaardenburg D, Rispens T.

Clin Chem Lab Med. 2018 Sep 25;56(10):1749-1758. doi: 10.1515/cclm-2017-0988. No abstract available.

20.

Can an increase in autoantibody levels predict arthritis in arthralgia patients?

van Beers-Tas MH, Stuiver MM, de Koning MHMT, van de Stadt LA, Geskus RB, van Schaardenburg D.

Rheumatology (Oxford). 2018 May 1;57(5):932-934. doi: 10.1093/rheumatology/kex506. No abstract available.

PMID:
29401313
21.

Evolution of autoantibody responses in individuals at risk of rheumatoid arthritis.

Falkenburg WJJ, van Schaardenburg D.

Best Pract Res Clin Rheumatol. 2017 Feb;31(1):42-52. doi: 10.1016/j.berh.2017.07.005. Epub 2017 Aug 24. Review.

PMID:
29221597
22.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

23.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2017 Nov 1;56(11):2025-2030. doi: 10.1093/rheumatology/kex284. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):771.

PMID:
28977504
24.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
25.

Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.

Tak PP, Doorenspleet ME, de Hair MJH, Klarenbeek PL, van Beers-Tas MH, van Kampen AHC, van Schaardenburg D, Gerlag DM, Baas F, de Vries N.

Ann Rheum Dis. 2017 Nov;76(11):1924-1930. doi: 10.1136/annrheumdis-2017-211351. Epub 2017 Aug 8.

26.

Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016.

Rasch LA, Boers M, Hill CL, Voshaar M, Hoogland W, de Wit M, Flurey C, Davis B, Hetland ML, Brahe CH, Gossec L, Wells GA, Tugwell P, Kuriya B, Goel N, Singh JA, Duarte C, Da Silva J, van Schaardenburg D, Proudman S, van Tuyl LHD; Working Group on the Patients’ Perspective on Remission in Rheumatoid Arthritis.

J Rheumatol. 2017 Dec;44(12):1889-1893. doi: 10.3899/jrheum.161111. Epub 2017 Aug 1.

PMID:
28765250
27.

Prevalence, Course, and Associated Factors of Pain in the Temporomandibular Joint in Early Rheumatoid Arthritis: Results of a Longitudinal Cohort Study.

Chin Jen Sem JP, van der Leeden M, Visscher CM, Britsemmer K, Turk SA, Dekker J, van Schaardenburg D, Lobbezoo F.

J Oral Facial Pain Headache. Summer 2017;31(3):233-239. doi: 10.11607/ofph.1606.

PMID:
28738108
28.

Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures.

Voshaar MAHO, Moghadam MG, Vonkeman HE, Ten Klooster PM, van Schaardenburg D, Tekstra J, Visser H, van de Laar MAFJ, Jansen TL.

J Rheumatol. 2017 Aug;44(8):1118-1124. doi: 10.3899/jrheum.160915. Epub 2017 May 15.

PMID:
28507187
29.

The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis.

Turk SA, Heslinga SC, Dekker J, Britsemmer L, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

J Rheumatol. 2017 May;44(5):580-586. doi: 10.3899/jrheum.161184. Epub 2017 Apr 1.

PMID:
28365582
30.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
31.

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.

PMID:
27991858
32.

The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission.

van Tuyl LH, Sadlonova M, Hewlett S, Davis B, Flurey C, Goel N, Gossec L, Heegaard Brahe C, Hill CL, Hoogland W, Kirwan J, Hetland ML, van Schaardenburg D, Smolen JS, Stamm T, Voshaar M, Wells GA, Boers M.

Ann Rheum Dis. 2017 May;76(5):855-861. doi: 10.1136/annrheumdis-2016-209835. Epub 2016 Nov 30.

PMID:
27903508
33.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

34.

Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):989-996. doi: 10.1002/acr.23112. Epub 2017 Jun 7.

35.

Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients.

Lübbers J, van Beers-Tas MH, Vosslamber S, Turk SA, de Ridder S, Mantel E, Wesseling JG, Reijm M, van Hoogstraten IM, Bijlsma JW, van Schaardenburg D, Bontkes HJ, Verweij CL.

Arthritis Res Ther. 2016 Sep 14;18(1):205. doi: 10.1186/s13075-016-1102-2.

36.

The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes.

de Jong TD, Lübbers J, Turk S, Vosslamber S, Mantel E, Bontkes HJ, van der Laken CJ, Bijlsma JW, van Schaardenburg D, Verweij CL.

Arthritis Res Ther. 2016 Jul 13;18:165. doi: 10.1186/s13075-016-1065-3.

37.

The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.

Konijn NP, van Tuyl LH, Boers M, van de Ven PM, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Lems WF, Nurmohamed MT.

Rheumatology (Oxford). 2016 Sep;55(9):1615-22. doi: 10.1093/rheumatology/kew221. Epub 2016 May 31.

PMID:
27247434
38.

Effectiveness of an integrated care intervention on supervisor support and work functioning of workers with rheumatoid arthritis.

van Vilsteren M, Boot CR, Twisk JW, van Schaardenburg D, Steenbeek R, Voskuyl AE, Anema JR.

Disabil Rehabil. 2017 Feb;39(4):354-362. doi: 10.3109/09638288.2016.1145257. Epub 2016 Apr 21.

PMID:
27097657
39.

One Year Effects of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis: Results of a Randomized Controlled Trial.

van Vilsteren M, Boot CR, Twisk JW, Steenbeek R, Voskuyl AE, van Schaardenburg D, Anema JR.

J Occup Rehabil. 2017 Mar;27(1):128-136. doi: 10.1007/s10926-016-9639-0.

40.

A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia.

van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D.

Arthritis Res Ther. 2016 Apr 1;18:76. doi: 10.1186/s13075-016-0975-4.

41.

In-shoe plantar pressure measurements for the evaluation and adaptation of foot orthoses in patients with rheumatoid arthritis: A proof of concept study.

Tenten-Diepenmaat M, Dekker J, Steenbergen M, Huybrechts E, Roorda LD, van Schaardenburg D, Bus SA, van der Leeden M.

Gait Posture. 2016 Mar;45:45-50. doi: 10.1016/j.gaitpost.2015.12.039. Epub 2015 Dec 29.

PMID:
26979882
42.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

43.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

44.

Process Evaluation of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis.

van Vilsteren M, Boot CR, Voskuyl AE, Steenbeek R, van Schaardenburg D, Anema JR.

J Occup Rehabil. 2016 Sep;26(3):382-91. doi: 10.1007/s10926-015-9624-z.

45.

How does established rheumatoid arthritis develop, and are there possibilities for prevention?

van Beers-Tas MH, Turk SA, van Schaardenburg D.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):527-42. doi: 10.1016/j.berh.2015.09.001. Epub 2015 Nov 14. Review.

PMID:
26697764
46.

Impact of Symptoms on Daily Life in People at Risk of Rheumatoid Arthritis.

van Tuyl LH, Stack RJ, Sloots M, van de Stadt LA, Hoogland W, Maat B, Raza K, van Schaardenburg D.

Musculoskeletal Care. 2016 Sep;14(3):169-73. doi: 10.1002/msc.1127. Epub 2015 Dec 17. No abstract available.

PMID:
26681409
47.

IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Wolbink G, Rispens T.

Arthritis Rheumatol. 2015 Dec;67(12):3124-34. doi: 10.1002/art.39299.

48.

Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients.

de Hair MJ, Leclerc P, Newsum EC, Maijer KI, van de Sande MG, Ramwadhdoebe TH, van Schaardenburg D, van Baarsen LG, Korotkova M, Gerlag DM, Tak PP, Jakobsson PJ.

PLoS One. 2015 Jul 30;10(7):e0133669. doi: 10.1371/journal.pone.0133669. eCollection 2015.

49.

Effective Treatment for Rapid Improvement of Both Disease Activity and Self-Reported Physical Activity in Early Rheumatoid Arthritis.

Konijn NP, van Tuyl LH, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, Nurmohamed M, van Schaardenburg D, Lems WF.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):280-4. doi: 10.1002/acr.22668.

50.

14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.

Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewé R, van der Heijde D, Murphy M, Marotta A.

J Rheumatol. 2015 Sep;42(9):1587-94. doi: 10.3899/jrheum.141385. Epub 2015 Jul 15.

PMID:
26178283

Supplemental Content

Loading ...
Support Center